What is CeQur?
Established in 2008 and headquartered in Switzerland, CeQur is dedicated to commercializing sophisticated yet user-friendly insulin-delivery devices. These tools are designed to enhance therapy adherence and empower individuals living with diabetes to better manage their condition. The company's focus on simplifying insulin delivery positions it as a key player in the diabetes care technology sector, aiming to improve patient outcomes and quality of life through accessible and effective devices.
How much funding has CeQur raised?
CeQur has raised a total of $391.6M across 4 funding rounds:
Series A
$29.6M
Series B
$27M
Series C
$215M
Private Equity
$120M
Series A (2010): $29.6M with participation from VI Partners and Endeavour Vision
Series B (2013): $27M, investors not publicly disclosed
Series C (2015): $215M supported by VI Partners, Tandem Diabetes Care, Credit Suisse, GMS Capital, Kingdon Capital Management, Woodford Investment Management, Arthurian Life Sciences, Federated Hermes Kaufmann Funds, Endeavour Vision, Ypsomed, and Bank of Communications Schroder Fund Management Co. Ltd.
Private Equity (2025): $120M, investors not publicly disclosed
Key Investors in CeQur
VI Partners
VI Partners is the longest-established Swiss VC firm, specializing in innovative Healthcare and Technology companies. They have a history of supporting ventures and have invested significantly in the sector.
Credit Suisse
Credit Suisse is a global financial services company that provides investment banking, private banking, and asset management services. Their involvement suggests a strategic financial backing for CeQur's growth initiatives.
Woodford Investment Management
Woodford Investment Management is a financial services firm known for managing various investment funds. Their participation indicates a focus on companies with strong growth potential in the healthcare sector.
What's next for CeQur?
The recent major strategic investment signals a pivotal phase for CeQur, likely enabling the company to scale its operations, expand its product development pipeline, and broaden its market reach. This influx of capital is anticipated to fuel further innovation in insulin delivery technology and reinforce CeQur's commitment to addressing the evolving needs of the diabetes community. The company is poised for significant advancements in its mission to improve diabetes management globally.
See full CeQur company page
